Literature DB >> 10797292

ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.

H Peng1, F Xu, R Pershad, K K Hunt, M L Frazier, A Berchuck, J W Gray, D Hogg, R C Bast, Y Yu.   

Abstract

In our previous work, we had characterized ARHI as an imprinted putative tumor-suppressor gene in ovarian and breast cancers. ARHI is expressed in primary breast and ovarian cell lines but largely absent from the corresponding malignant tumors. Moreover, the non-imprinted functional allele is typically deleted in malignant cells. Since ARHI had been mapped to 1p31, a common deletion site in breast and ovarian cancer and male germ-cell tumors, in this study, we set out to define precisely the physical location of ARHI at 1p31 and to determine if this location lies within the smallest common region of deletion in breast and ovarian cancers. To this end, we first carried out radiation hybrid mapping of ARHI and surrounding markers, followed by a high-resolution study of loss of heterozygosity at 1p31 in 49 ovarian and breast cancers. Combining a radiation hybrid map and a physical map of the region encompassing ARHI, 3 discrete regions of minimal deletion were found at 1p31 in breast and ovarian cancers. ARHI is the most common deletion region at 1p31. Two other less common regions of deletion were found centromeric to this gene. One of them centered on D1S207 and the other one included and was proximal to D1S488. We also confirmed the preferential loss of non-imprinted functional allele in 7 of 9 tumor specimens. These data support the possibility that ARHI is a tumor-suppressor gene and suggest that additional tumor-suppressor genes may lie proximal to ARHI at 1p31. The data obtained from our study should aid in the identification and characterization of genes in this novel imprinted region. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797292     DOI: 10.1002/(sici)1097-0215(20000601)86:5<690::aid-ijc14>3.0.co;2-k

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Over-expression of ARHI decreases tumor growth, migration, and invasion in human glioma.

Authors:  Jing Chen; Songsheng Shi; Weizhong Yang; Chunmei Chen
Journal:  Med Oncol       Date:  2014-01-24       Impact factor: 3.064

3.  Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.

Authors:  Ying Li; Mei Liu; Yanjun Zhang; Chun Han; Junhao You; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2013-06-26

4.  Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis.

Authors:  M Christine Hollander; Robyn T Philburn; Andrew D Patterson; Susana Velasco-Miguel; Errol C Friedberg; R Ilona Linnoila; Albert J Fornace
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

5.  Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells.

Authors:  Ying Li; Li Shi; Chun Han; Yishang Wang; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2012-04-14

6.  Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro.

Authors:  Xiaohong Wu; Li Liang; Liangliang Dong; Zhe Yu; Xiaoqing Fu
Journal:  Mol Biol Rep       Date:  2012-12-18       Impact factor: 2.316

7.  Aplasia ras homologous member I gene and development of glial tumors.

Authors:  S Yakut; Mr Tuncer; M Berker; E Goksu; I Gurer; On Ozes; G Luleci; Sb Karauzum
Journal:  Balkan J Med Genet       Date:  2011-06       Impact factor: 0.519

8.  Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.

Authors:  Chun-Fang Zou; Luoqi Jia; Hongyan Jin; Ming Yao; Naiqing Zhao; Jin Huan; Zhen Lu; Robert C Bast; Youji Feng; Yinhua Yu
Journal:  BMC Cancer       Date:  2011-01-19       Impact factor: 4.430

9.  MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone.

Authors:  Juan Cui; Joanna B Eldredge; Ying Xu; David Puett
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

10.  Loss of DNA methylation at imprinted loci is a frequent event in hepatocellular carcinoma and identifies patients with shortened survival.

Authors:  Sumadi Lukman Anwar; Till Krech; Britta Hasemeier; Elisa Schipper; Nora Schweitzer; Arndt Vogel; Hans Kreipe; Ulrich Lehmann
Journal:  Clin Epigenetics       Date:  2015-10-15       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.